Author(s): Vitarani D. A. Ningrum, Priska C. Sukemi, Khoerul A. Rhidohan, Endang Yuniarti


DOI: 10.52711/0974-360X.2022.00431   

Address: Vitarani D. A. Ningrum1*, Priska C. Sukemi2, Khoerul A. Rhidohan2, Endang Yuniarti3,4
1Pharmacy Practice Laboratory, Department of Pharmacy, Universitas Islam Indonesia, Indonesia.
2Research Assistant, Department of Pharmacy, Universitas Islam Indonesia, Indonesia.
3PKU Muhammadiyah Hospital, Yogyakarta, Indonesia.
4STIKES Muhammadiyah Gombong, Central Java, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 6,     Year - 2022

Therapy to control seizures primarily utilizes drugs to date, including carbamazepine. However, carbamazepine has a narrow therapeutic index and is auto-inductive and potential to induce serious adverse reactions, such as Stevens-Johnson Syndrome. This has placed carbamazepine among the priority drugs for which the utilization should be evaluated to ensure safety and effectiveness. This study analyzed the indication, dose, clinical response, and adverse drug reaction (ADR) of carbamazepine by five hospitals in Yogyakarta. The research employed a retrospective cross-sectional design for patients with epilepsy who received carbamazepine for a minimum of 3 days. Patients’ demographics, diagnosis, carbamazepine dose and clinical response, ADR, and concomitant drugs interacting with carbamazepine were collected from medical records during one year of the study. The study involved 78 patients with a majority of male with age of 44.3±13.3 years. The highest indication of carbamazepine was for secondary-type epilepsy (17.95%) with an average maintenance dose of 423.94±135.65 mg/day. Carbamazepine discrepancy was found in absence-type epileptic with an average dose higher than that for other seizure types. Meanwhile, more than 80% seizures could be controlled by carbamazepine monotherapy or its combination. This study found that 16.67% of patients suffered from ADR, particularly a nervous system disorder, with no serious ADR reported. An effective approach is required to improve the appropriateness of antiepileptic drug selection based on the seizure types. In addition, the average maintenance dose of CBZ found in this study, which is relatively lower than those found in studies involving different populations, needs further pharmacogenetic studies of carbamazepine.

Cite this article:
Vitarani D. A. Ningrum, Priska C. Sukemi, Khoerul A. Rhidohan, Endang Yuniarti. A Study of Carbamazepine Utilization in the Hospitals in Yogyakarta Special Province. Research Journal of Pharmacy and Technology. 2022; 15(6):2577-4. doi: 10.52711/0974-360X.2022.00431

Vitarani D. A. Ningrum, Priska C. Sukemi, Khoerul A. Rhidohan, Endang Yuniarti. A Study of Carbamazepine Utilization in the Hospitals in Yogyakarta Special Province. Research Journal of Pharmacy and Technology. 2022; 15(6):2577-4. doi: 10.52711/0974-360X.2022.00431   Available on:

1.    Capule F, Tragulpiankit P, Mahasirimongkol S, et al. Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. The Pharmacogenomics Journal. 2020;20(3):533-541.
2.    Garcia JBS, Ferro LSG, Carvalho AB, da Rocha RM, de Souza LML. Severe carbamazepine-induced cutaneous reaction in the treatment of post-herpetic neuralgia. Case report. Rev Bras Anestesiol. 2010;60(4):429-437.
3.    Masuka JT, Muzopambwa G, Khoza S, Chibanda D. An Interesting Case of Carbamazepine-Induced Stevens–Johnson Syndrome. Drug Saf Case Rep. 2018;6(1).
4.    Yuliwulandari R, Kristin E, Prayuni K, et al. Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics. 2017;18(18):1643-1648.
5.    Khoo ABS, Ali FR, Yiu ZZN, Ferguson JE. Carbamazepine induced Stevens-Johnson syndrome. Case Reports. 2016;bcr2016214926.
6.    Nasir SA, Tan HL, Tan HJ, Hussaini HM, Ramli R. Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription. Case Reports in Dentistry.
7.    Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025-1032.
8.    Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013;18(Suppl 1):S81-S85.
9.    Figueras A. Review of the Evidence to Include TDM in the Essential in Vitro Diagnostics Lost and Prioritization of Medicines to be Monitored. Published online 2019.
10.    Bialer M, Levy RH, Perucca E. Does Carbamazepine Have a Narrow Therapeutic Plasma Concentration Range? Therapeutic Drug Monitoring. 1998;20(1):56-59.
11.    Andayani P, Soetomenggolo TS, Hadinegoro SRS. Clinical Evaluation of Epilepsy Treatment with Carbamazepine in Children. Sari Pediatri. 2016;2(3):126-131.
12.    George J. Evaluation of Drug Utilization and Analysis of Anti- Epileptic Drugs at Tertiary Care Teaching Hospital. Indian Journal of Pharmacy Practice. 2016;9(3):189-194.
13.    Kenyon K, Mintzer S, Nei M. Carbamazepine treatment of generalized tonic–clonic seizures in idiopathic generalized epilepsy. Seizure. 2014;23(3):234-236.
14.    Rakitin A, Kõks S, Haldre S. Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. Seizure - European Journal of Epilepsy. 2016;38:11-16.
15.    Luef G, Taubøll E. Gender issues in epilepsy – Difference in management of epilepsy. Seizure. 2015;28:1-2.
16.    Ahmed GF, Brundage RC, Marino SE, et al. Population Pharmacokinetics of Unbound and Total Drug Concentrations Following Intravenously Administered Carbamazepine in Elderly and Younger Adult Patients With Epilepsy. J Clin Pharmacol. 2013;53(3):276-284.
17.    Lee SK, Epilepsy in the Elderly: Treatment and Consideration of Comorbid Diseases. J Epilepsy Res. 2019;9(1):27-35.
18.    Seo J-G, Cho YW, Kim KT, et al. Pharmacological Treatment of Epilepsy in Elderly Patients. Journal of Clinical Neurology. 2020;16(4):556-561.
19.    Punyawudho B, Ramsay RE, Brundage RC, Macias FM, Collins JF, Birnbaum AK. Population Pharmacokinetics of Carbamazepine in Elderly Patients. Ther Drug Monit. 2012;34(2):176-181.
20.    Kim JY, Lee J, Ko Y-J, et al. Multi-Indication Carbamazepine and the Risk of Severe Cutaneous Adverse Drug Reactions in Korean Elderly Patients: A Korean Health Insurance Data-Based Study. PLOS ONE. 2013;8(12):e83849.
21.    Intravooth T, Staack AM, Juerges K, Stockinger J, Steinhoff BJ. Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients. Epilepsy Research. 2018;143:7-10.
22.    Bruun E, Virta LJ, Kälviäinen R, Keränen T. Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: A Finnish retrospective study. Seizure. 2015;31:27-32.
23.    Chen L-A, Cheng S-J, Jou S-B. Epilepsy in the Elderly. International Journal of Gerontology. 2012;6(2):63-67.
24.    Glauser T, Ben‐Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563.
25.    Liu L, Zheng T, Morris MJ, et al. The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther. 2006;319(2):790-798.
26.    Panayiotopoulos CP. Typical absence seizures and their treatment. Archives of Disease in Childhood. 1999;81(4):351-355.
27.    Kaur U, Chauhan I, Gambhir IS, Chakrabarti SS. Antiepileptic drug therapy in the elderly: a clinical pharmacological review. Acta Neurol Belg. 2019;119(2):163-173.
28.    Seo J-G, Cho YW, Kim KT, et al. Pharmacological Treatment of Epilepsy in Elderly Patients. J Clin Neurol. 2020;16(4):556-561.
29.    Ruiz-Giménez J, Sánchez-Álvarez JC, Cañadillas-Hidalgo F, Serrano-Castro PJ. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure. 2010;19(7):375-382.
30.    Mahmoud SH, Zhou XY, Ahmed SN. Managing the patient with epilepsy and renal impairment. Seizure - European Journal of Epilepsy. 2020;76:143-152.
31.    Camacho Velásquez JL, Rivero Sanz E, Sanabria Sanchinel AA, Santos Lasaosa S, Mauri Llerda JA. Difficulties in diagnosing absence seizures in adults. Neurologia. 2018;33(6):403-405.
32.    Ozdemir HH, Demir CF, Cura HS. Absence status seen in an adult patient. J Neurosci Rural Pract. 2013;4(3):342-344.
33.    Glauser T, Ben‐Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-563.
34.    Goldenberg MM. Overview of Drugs Used For Epilepsy and Seizures. P T. 2010;35(7):392-415.
35.    Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures. Epilepsy Res Treat. 2015;2015.
36.    Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol. 2016;16(1).
37.    Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis. Epilepsia. 2019;60(11):2245-2254.
38.    Vernachio K, Lovett AW, Williams J. A review of withdraw strategies for discontinuing antiepileptic therapy in epilepsy and pain management. Pharm Pharmacol Int J. 2015;Volume 3(Issue 1).
39.    Kumar S, Sarangi SC, Tripathi M, Ramanujam B, Gupta YK. Seizure recurrence risk in persons with epilepsy undergoing antiepileptic drug tapering. Acta Neurol Scand. 2019;141(1):65-76.
40.    Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020;104(Pt A):106939.
41.    Brodie MJ, Sills GJ. Combining antiepileptic drugs—Rational polytherapy? Seizure, 20(5). Published online 2011:369-375.
42.    Eshiet UI, Ubaka CM, Ukwe CV. Infrequent Monitoring of the Effects of Valproate and Carbamazepine Therapy in Patients With Epilepsy in Nigeria. J Cent Nerv Syst Dis. 2020;12:117957352092593.
43.    Istikharah R, Hartienah SD, Vitriyani S, Ningrum. Allele Frequency of Carbamazepine Major Efflux Transporter Encoding Gene ABCB1 C3435T among Javanese-Indonesian Population | Open Access Macedonian Journal of Medical Sciences. Open Access Maced J Med Sci. 2020;8(A):406-413.
44.    Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867-1879.
45.    Pham TH, Huynh HTM, Vo HT, Tran HM. Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients. Research Journal of Pharmacy and Technology. 2020;13(6):2802-2806.  
46.    Fricke-Galindo I, L Lerena A, Jung-Cook H, López-López M. Carbamazepine adverse drug reactions. Expert Review of Clinical Pharmacology. 2018;11(7):705-718.
47.    Lincy S, Greeshma M, Maheswari E, Tharanath S, Viswam S. An Empirical Study to assess the Pattern and Predictors of Adverse Drug Reactions associated with Polypharmacy in the Department of General Medicine. Research Journal of Pharmacy and Technology. 2018;11(11):5042-5048.
48.    M RN, Kumar S, C BRK, et al. A Prospective Observational Study on Adverse Drug Reactions in General Medicine Department of a Tertiary Care Teaching Hospital. Research Journal of Pharmacy and Technology. 2019;12(5):2289-2298.
49.    de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507-1515.
50.    Kumar S, Badruddeen, Singh SP, Juber A, Khan MI. Evaluation of Dermatological Adverse Drug Reactions in a Tertiary Care Hospital of Northern India. Research Journal of Pharmacy and Technology. 2019;12(7):3517-3521.
51.    Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia. 2013;54(1):11-27.
52.    Zhang X, Zhong R, Chen Q, Li M, Lin W, Cui L. Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis. J Int Med Res. 2020;48(3):030006052090260.
53.    Niveditha, Srikanth, H S, R S. Antiepileptic drug use and risk of development of fracture - A case control study. Research Journal of Pharmacy and Technology. 2013;6(11):1237-1239.
54.    Tamilselvan T, C AR, Raj A, M LP, Varghese N, Paul SP. Prescription Analysis of Antiepileptic Drugs in a Tertiary Care Hospital. Asian Journal of Pharmacy and Technology. 2018;8(1):43-46.
55.    Singh AR, Tiwari R. A Review on Pharmacovigilance a Powerful Weapon for Tracking Safety and Efficacy of Drugs. Research Journal of Pharmacy and Technology. 2011;4(6):867-871.
56.    Khairnar A, Gade PR. Interventional Improvement in Hospital Based Intensive Monitoring of Adverse Event. Research Journal of Pharmacy and Technology. 2011;4(9):1443-1448.¬

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available